Gene therapy represents a transformative approach to treating neurodegenerative diseases by delivering therapeutic genetic material to target cells in the central nervous system. Unlike small molecule drugs or biologics that require repeated administration, gene therapy offers the potential for long-lasting or even curative effects through a single treatment. Recent advances in viral vector technology, delivery methods, and gene editing tools have accelerated clinical development across Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other neurodegenerative conditions[1]. [1]
Gene replacement therapy delivers a functional copy of a disease-causing gene to compensate for loss-of-function mutations. This approach is particularly relevant for autosomal recessive diseases and conditions where increasing protein expression provides therapeutic benefit. [2]
Applications in Neurodegeneration: [3]
| Target | Disease | Approach | Status | [4]
|--------|---------|----------|--------| [5]
| GBA | PD/Gaucher | AAV-GBA1 | Phase I/II | [6]
| PARK2 (Parkin) | Early-onset PD | AAV-PARKIN | Preclinical | [7]
| PINK1 | PD | AAV-PINK1 | Preclinical |
| CHCHD10 | ALS/FTD | AAV-CHCHD10 | Preclinical |
| FXN | Friedreich's ataxia | AAV-FXN | Phase I/II |
RNA interference (RNAi) and antisense oligonucleotide (ASO) technologies enable selective reduction of toxic protein expression. This approach is ideal for gain-of-function mutations and diseases driven by protein overexpression[2].
Key Technologies:
Clinical Applications:
| Agent | Target | Disease | Phase | Company |
|---|---|---|---|---|
| Tofersen | SOD1 | ALS | Approved | Biogen |
| Nusinersen | SMN1 | SMA | Approved | Biogen |
| Inotersen | TTR | hATTR Polyneuropathy | Approved | Ionis |
| IONIS-HTTRx | HTT | Huntington's | Phase I/II | Ionis/Rochester |
CRISPR-Cas9 and related technologies enable precise modification of genomic DNA, offering potential for correcting disease-causing mutations or disrupting toxic gene expression[3].
Editing Strategies:
Emerging Approaches:
AAV vectors are the dominant platform for CNS gene therapy due to their favorable safety profile and long-term expression[4].
Serotype Tropism:
| Serotype | CNS Target | Notes |
|---|---|---|
| AAV9 | Neurons, astrocytes | Most commonly used |
| AAV2 | Neurons | Historical, well-characterized |
| AAV1 | Motor neurons | Good for ALS |
| AAV-PHP.B | CNS-wide | High transduction |
| AAV-PHP.eB | CNS-wide | Improved version |
Key Advantages:
Challenges:
Lentiviral vectors can deliver larger genetic payloads and integrate into the host genome, providing stable expression.
Applications:
Alternative Approaches:
Gene Therapy Targets:
Amyloid-related genes:
Tau-related genes:
Neuroprotective genes:
Clinical Trials:
| Trial | Vector | Gene | Phase | Status |
|---|---|---|---|---|
| NCT04480350 | AAV | BDNF | I | Recruiting |
| NCT03788707 | AAV | NGF | I/II | Completed |
| NCT05838430 | AAV | APOE2 | I | Planning |
Gene Therapy Approaches:
Dopamine restoration:
Neuroprotection:
Disease-modifying:
Approved and Advanced Programs:
| Product | Target | Approach | Status |
|---|---|---|---|
| Upstaza | AADC | AAV2-AADC | Approved (EU) |
| ABBV-951 | TH/AADC/GCH1 | Lentiviral | Phase III |
| AAV-GAD | GAD65/67 | Gene addition | Phase II |
Gene Therapy Strategies:
SOD1 silencing (Tofersen - approved):
C9orf72 targeting:
FUS, TARDBP targeting:
Neuroprotective factors:
Clinical Pipeline:
| Agent | Target | Route | Phase |
|---|---|---|---|
| Tofersen | SOD1 | Intrathecal | Approved |
| ION363 | C9orf72 | Intrathecal | Phase I/II |
| WVE-004 | C9orf72 | Intrathecal | Phase I/II |
| ASO-Targeted | FUS | Intrathecal | Preclinical |
Gene Therapy Approaches:
HTT gene silencing:
Neuroprotective strategies:
Clinical Status:
The BBB remains a major hurdle for CNS gene therapy. Current strategies include:
Direct CNS injection:
BBB-disrupting techniques:
Engineered vectors:
Mitigation Strategies:
| Type | Biomarker | Application |
|---|---|---|
| Target engagement | Protein levels in CSF | Measure drug effect |
| Disease modification | Neurofilament light chain (NfL) | Track progression |
| Imaging | PET tracers | Monitor pathology |
| Clinical | Motor/cognitive scores | Functional outcomes |
| Product | Disease | Approval |
|---|---|---|
| Upstaza | AADC deficiency | 2022 (EU) |
| Zolgensma | SMA | 2019 (US/EU) |
| Spinraza | SMA | 2016 (US) |
| Tofersen | SOD1-ALS | 2023 (US) |
Viral vector evolution:
Gene editing advances:
Combination approaches:
Gowing G, Svendsen S, Svendsen CN. Gene therapy for neurodegenerative diseases: progress and prospects. Nat Rev Neurol. 2024;20(5):293-307. 2024. ↩︎
Kuiper EJ, Broekman MD. RNA therapeutics for neurodegenerative disease. Brain. 2023;146(8):3123-3137. 2023. ↩︎
Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019;20(8):490-507. 2019. ↩︎
Wang D, Gao G. AAV vector delivery to the central nervous system. Mol Ther. 2024;32(1):45-59. 2024. ↩︎
Tofersen for SOD1-ALS: FDA approval package. Amyotroph Lateral Scler Frontotemporal Degener. 2023;24(Suppl 1):1-12. 2023. ↩︎
Coune PG, Schneider BL, Aebischer P. Parkinson's disease: gene therapies. Nat Rev Neurol. 2022;18(3):143-156. 2022. ↩︎
Leavitt BR, Tabrizi SJ. Antisense oligonucleotides for Huntington's disease: where are we now? Nat Rev Neurol. 2024;20(2):71-72. 2024. ↩︎